copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Overview | Xeris Biopharma Holdings, Inc. Xeris Pharmaceuticals (XERS) improves patient lives by developing and commercializing innovative, ready-to-use therapeutic medicine
Products - Xeris Biopharma Holdings, Inc. Gvoke ®, Gvoke HypoPen ®, XeriSol TM, XeriJect ®, Xeris Pharmaceuticals ®, Ogluo ®, Keveyis ®, Recorlev ®,Gvoke HypoPen 2-Pack TM, XerisCareConnection TM, PPP MentorConnect TM, droplet design, and their associated logos are trademarks owned by or licensed to Xeris Pharmaceuticals, Inc , a wholly owned subsidiary of Xeris Biopharma
Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 . . . Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing’s syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis®, a proven therapy for primary periodic paralysis
Pipeline - Xeris Biopharma Holdings, Inc. Currently, Xeris is working on a number of formulation feasibility programs for its own as well as its partners’ pipeline in the areas of small molecules, peptides, biologics, and monoclonal antibodies
Careers - Xeris Biopharma Holdings, Inc. At Xeris, we’ve harnessed our entrepreneurial spirit and combined our strengths in the quest to solve real treatment administration challenges We'd love for you to come join us
Xeris Announces Approval of Supplemental New Drug Application (sNDA) of . . . Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing’s syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, and a gastrointestinal motility inhibitor when used during radiology exams as a diagnostic aid; and Keveyis®, a proven therapy for primary periodic
Financials SEC Filings | Xeris Biopharma Holdings, Inc. Gvoke ®, Gvoke HypoPen ®, XeriSol TM, XeriJect ®, Xeris Pharmaceuticals ®, Ogluo ®, Keveyis ®, Recorlev ®,Gvoke HypoPen 2-Pack TM, XerisCareConnection TM, PPP MentorConnect TM, droplet design, and their associated logos are trademarks owned by or licensed to Xeris Pharmaceuticals, Inc , a wholly owned subsidiary of Xeris Biopharma Holdings, Inc All other trademarks are the property of
Xeris Biopharma Reports Third Quarter 2023 Financial Results CHICAGO--(BUSINESS WIRE)--Nov 9, 2023-- Xeris Biopharma Holdings, Inc (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the third quarter and nine months ended September 30
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its . . . Xeris has three commercially available products; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis®, a proven therapy for primary periodic paralysis, and Recorlev® for the treatment of endogenous Cushing’s syndrome